



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1633
KALTOFT, et al.)	Examiner:
Serial No.: 09/720,371)	Washington, D.C.
Filed: April 30, 2001)	October 22, 2001
For: METHODS OF EXPANDING AND SELECTING DISEASE...)	Docket No.: KALTOFT=1

RECEIVED
OCT 29 2001
TECH CENTER 1600/2900

8/B
KO
11/3/01

SECOND PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

S i r :

IN THE CLAIMS

Please cancel claims 49.

Please amend claims 1, 6, 12, 14, 17, 19, 22, 24, 25, 29, 34, 37, 39, 40, 44 and 52 as follows:

1 (amended). A method of continuously culturing normal, human, disease associated, antigen activated T-cells comprising

(a) obtaining a tissue sample from a mammal, the sample comprising disease associated, antigen activated T-cells and disease associated antigen or antigens, or

obtaining T-cells, comprising disease associated, antigen activated T-cells, and antigen-presenting cell from said mammal and mixing said cells with a disease associated antigen or antigens, and

(b) culturing said tissue sample or said mixture of cells and antigen(s) in the presence of at least two factors which promote T-cell growth and optionally one or more additional compounds, where said mammal is a human being.

6 (amended). A method according to claim 1, wherein each of the cytokines is used in a concentration of at least 1 nM, preferably more than 2.5 nM.

12 (amended). A method according to claim 1, wherein the disease is selected from the group consisting of chronic inflammatory bowel disease, multiple sclerosis, type I diabetes, rheumatoid arthritis, psoriasis, atopic dermatitis, asthma, malignant melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the uterus, prostatic cancer, cutaneous lymphoma, hepatic carcinoma, rejection-related disease, and Graft-versus-host-related

B¹

B²

B³

sep 11, 2